HIM
AKRO

Hillsdale Investment Management’s Akero Therapeutics AKRO Stock Holding History

Hillsdale Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$5.06K – 561
2023
Q3 		$5.06K Buy
100
+20
+25% +$931 ﹤0.01% 512
2023
Q2 		$3.73K Sell
80
-17,820
-100% -$817K ﹤0.01% 481
2023
Q1 		$685K Buy
+17,900
New +$798K 0.06% 244

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hillsdale Investment Management's AKRO Position: Q4 2023 in Review

Hillsdale Investment Management sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 100 shares — an estimated $5.06K sold.

Hillsdale Investment Management first reported a position in AKRO in Q1 2023 and held it in 3 quarters. The position peaked at $685K in Q1 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Hillsdale Investment Management reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 100 Akero Therapeutics shares in Q4 2023, an estimated $5.06K.
  • Hillsdale Investment Management first reported a position in Akero Therapeutics in Q1 2023 and held it in 3 quarters.
  • Hillsdale Investment Management's Akero Therapeutics position peaked at $685K in Q1 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Hillsdale Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.